Drugs / F8IL10
Trials 4 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT07245992 | Jan 2026 → Sep 2028 expected | rheumatoid arthritis | Philogen S.p.A. | Recruiting | No outcome recorded |
| Phase 1 | NCT05622175 | Mar 2023 → Dec 2025 | rheumatoid arthritis | Philogen S.p.A. | Withdrawn | No outcome recorded |
| Phase 1 | NCT02076659 | Sep 2011 → Apr 2017 | rheumatoid arthritis | Philogen S.p.A. | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT02270632 | Oct 2014 → Apr 2019 | rheumatoid arthritis | Philogen S.p.A. | Terminated | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | F8IL10 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07245992 ↗ |
| Modality | Monoclonal antibody | “Human Monoclonal Antibody-cytokine Fusion Protein F8IL10” NCT02076659 ↗ |
| Route | Subcutaneous | “F8IL10 will be administered as subcutaneous (s.c.) injections.” NCT02076659 ↗ |